GLUEMonte Rosa Therapeutics, IncSigning up patients
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
Castration-Resistant Prostate Cancer (CRPC) · Castration-Resistant Prostate Cancer · Prostate Cancer · Prostate Cancer (Adenocarcinoma)
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.7
2 insiders sold shares within a month
Since Jul 16, 2026 · was worth 10, fading over time
Worry score3
Score over time
- Stage
- Phase 2
- Patients
- 25 (planned)
- Started
- Aug 18, 2026
- Main results expected
- Oct 2027
- Fully finished
- Apr 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Assess the efficacy of MRT-2359 combined with apalutamide
Measured over: 14 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 2.7, since 2026-07-16, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07745361 · record last updated 2026-11-05 · checked 2026-11-09 15:47 UTC